The Development and Content Validation of the Sjögren’s Related Quality of Life Instrument (SRQoL)
Authors:
Open Access
- 10 October 2024
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 11 (6) , 1591-1609
Abstract
Introduction Several clinical outcome assessment (COA) instruments assess Sjögren’s disease (Sjögren’s) symptoms, but do not provide comprehensive assessment of the health-related quality of life (HRQoL) impact of Sjögren’s. This study aimed to develop a patient-reported outcome (PRO) instrument for the assessment of HRQoL, intended for use in clinical trials and clinical practice in the assessment of treatment benefit. Methods Review of study sponsor proprietary data and qualitative interviews informed the development of a conceptual model, the Sjögren’s Related Quality of Life (SRQoL) and patient global impression of severity (PGI-S) and change (PGI-C) items. Combined concept elicitation and cognitive debriefing interviews with patients with Sjögren’s explored their HRQoL impact experience and content validity of the SRQoL and PGI items. Results Twenty participants were interviewed about their Sjögren’s experience. Following inductive analysis of interviews, concepts were categorized into eight domains: emotional well-being (e.g., worry and stress; n = 20/20; 100%), sleep (e.g., daytime sleepiness and waking up during the night; n = 20/20; 100%), activities of daily living (e.g., difficulty looking at screens and difficulty driving; n = 20/20; 100%), cognition (e.g., concentration difficulties and word finding difficulties; n = 19/20; 95.0%), physical functioning (e.g., difficulty walking and difficulty exercising; n = 19/20; 95.0%), social and family functioning (e.g., dependent on others and relationship difficulties; n = 17/20; 85.0%), work (n = 15/20; 75.0%), and sexual functioning (n = 12/20; 60.0%). SRQoL and PGI items, instructions, response options, and recall period were well understood and relevant to participants. Conclusions The SRQoL is a new PRO instrument to assess Sjögren’s impact on HRQoL, developed in accordance with regulatory guidance. This study provides considerable insight into the patient experience of Sjögren’s and evidence to support the content validity of the SRQoL. Future research should evaluate the psychometric properties of the SRQoL to support its use in clinical trials and clinical practice and further validate its use as an assessment of treatment benefit.Keywords
Funding Information
- Novartis
This publication has 49 references indexed in Scilit:
- Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’sRheumatology and Therapy, 2022
- The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York CountyArthritis Care & Research, 2019
- 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient CohortsArthritis & Rheumatology, 2016
- Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic TrialArthritis Care & Research, 2016
- Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren SyndromeJAMA, 2014
- European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete Picture of Primary Sjögren's Syndrome PatientsArthritis Care & Research, 2013
- American College of Rheumatology classification criteria for Sjögren's syndrome: A data‐driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance CohortArthritis Care & Research, 2012
- Choice of recall period for patient-reported outcome (PRO) measures: criteria for considerationQuality of Life Research, 2011
- The applications of PROs in clinical practice: what are they, do they work, and why?Quality of Life Research, 2008
- Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)Arthritis & Rheumatism, 2004